$KALV News
Last published 5mo ago
- 5mo agoKALVChiesi Group Completes Acquisition of KalVista PharmaceuticalsBusiness WirePositioned to Expand Patient Access and Accelerate Impact in Rare Diseases Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its
- 5mo agoKALVKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary AngioedemaBusiness WirePresentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11
- 6mo agoKALVChiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease PortfolioBusiness WireHighlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi's rare immunology portfolio the
- 6mo agoACOGKALVSUPNAlpha Cognition Strengthens Its Board of Directors with Appointment of Bethany SensenigBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 7mo agoKALVKalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m. EST A live
- 7mo agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375
- 7mo agoKALVKalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership ConferenceBusiness WireInterim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced
- 7mo agoKALVKalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate UpdateBusiness Wire$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting
- 7mo agoKALVKalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership ConferenceBusiness WireNew interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that five
- 7mo agoKALVKalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company's eight months fiscal year 2025 financial results and provide a
- 8mo agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted one newly-hired employee inducement options to purchase an aggregate of 6,750 shares
- 8mo agoKALVKalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)Business WirePresentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
- 8mo agoKALVKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference on
- 8mo agoKALVKalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE GuidelineBusiness WireGuideline recommends ensuring on-demand treatment is available anytime, anywhere and prioritizes early intervention and rapid self-administration, reinforcing the unique value of EKTERLY KalVista Pharmaceuticals, Inc.
- 9mo agoKALVKalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual MeetingBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in
- 9mo agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750
- 1y agoKALVKalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial ResultsBusiness WireUS launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral
- 1y agoKALVKalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific MeetingBusiness WireKONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric
- 1y agoKALVKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel 2025 Healthcare Conference on
- 1y agoKALVKalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational
- 1y agoKALVKalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific MeetingBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma &
- 1y agoKALVKalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in EuropeBusiness WireFindings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies KalVista Pharmaceuticals, Inc.
- 1y agoKALVKalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People OfficerBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome
- 1y agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000
- 1y agoKALVKalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of DirectorsBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit
- 1y agoKALVKalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy CongressBusiness WireKalVista Pharmaceuticals, Inc.
- 1y agoKALVKalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031Business WireKalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the "notes") in a private
- 1y agoKALVKalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior NotesBusiness WireKalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes
- 1y agoKALVKalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary AngioedemaBusiness WireFirst European launch of EKTERLY expected in Germany Q4 2025 EKTERLY now approved in the US, EU, UK and Switzerland with additional regulatory applications under review in key global markets KalVista
- 1y agoKALVKalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKALVKalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial ResultsBusiness Wire-EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through
- 1y agoKALVKalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoKALVKalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for
- 1y agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 5,000
- 1y agoKALVKalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET. A
- 1y agoKALVMGXMetagenomi Appoints Laurence Reid, PhD to its Board of DirectorsGlobeNewswireEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its
- 1y agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 44,000
- 1y agoKALVKalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema AttacksBusiness WireIf approved, sebetralstat will be the first and only oral on-demand treatment for HAE in the European Union (EU) European Commission decision expected by early October 2025 KalVista Pharmaceuticals, Inc.
- 1y agoKALVKalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaBusiness WireEKTERLY to be added to the Orphan Register and awarded 10 years of market exclusivity KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of
- 1y agoKALVKalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial ResultsBusiness Wire– Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway – – Six additional global regulatory submissions under review – –
- 1y agoKALVKalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaBusiness WireFirst new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or
- 1y agoKALVApproval of Ekterly, Nda #219301 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 07/03/2025; Drug Name: Ekterly, Nda #219301; Active Ingredients: SEBERTRALSTAT; Company: Kalvista Pharmaceuticals Ltd; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 219301
- 1y agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000
- 1y agoKALVKalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in CanadaBusiness Wire-Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada- -Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with
- 1y agoKALVKalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term ProphylaxisBusiness Wire–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications– –In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks,
- 1y agoKALVKalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource ConstraintsBusiness WireFDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that
- 1y agoKALVKalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United
- 1y agoKALVKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000
- 1y agoKALVKalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema ManagementBusiness Wire–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials– –Sebetralstat data demonstrated rapid relief and resolution of severe HAE
- 1y agoKALVKalVista Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceBusiness WireKalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 a.m. ET. A live